应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02607 上海医药
未开盘 12-31 12:08:15
12.620
+0.000
0.00%
最高
12.700
最低
12.560
成交量
197.36万
今开
12.600
昨收
12.620
日振幅
1.11%
总市值
467.95亿
流通市值
115.98亿
总股本
37.08亿
成交额
2,489万
换手率
0.21%
流通股本
9.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
上海医药拟并表上海和黄药业 提升中药产品销售及国际化能力
证券日报 · 01:34
上海医药拟并表上海和黄药业 提升中药产品销售及国际化能力
上海医药拟9.95亿元收购上海和黄药业10%股权
每日经济新闻 · 00:15
上海医药拟9.95亿元收购上海和黄药业10%股权
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
美港电讯 · 01-01 23:36
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
第一财经 · 01-01 22:40
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
和黄医药再次剥离中药资产 上海医药拟斥资近10亿元实控和黄药业
第一财经 · 01-01 21:25
和黄医药再次剥离中药资产 上海医药拟斥资近10亿元实控和黄药业
上海医药与云南白药2025年日常/持续关连交易金额上限为19亿元
财中社 · 01-01 20:43
上海医药与云南白药2025年日常/持续关连交易金额上限为19亿元
上海医药最新公告：决定终止三个研发项目的临床试验及后续开发
证券之星 · 01-01 19:00
上海医药最新公告：决定终止三个研发项目的临床试验及后续开发
上海医药(02607)拟以9.95亿元收购上海和黄10%股权
智通财经 · 01-01 18:20
上海医药(02607)拟以9.95亿元收购上海和黄10%股权
上海医药拟9.95亿元收购上海和黄药业10％股权
大河财立方 · 01-01 17:30
上海医药拟9.95亿元收购上海和黄药业10％股权
上海医药(601607.SH)：拟收购上海和黄药业10%股权暨成为实际控制人
格隆汇 · 01-01 17:01
上海医药(601607.SH)：拟收购上海和黄药业10%股权暨成为实际控制人
上海医药最新公告：拟收购上海和黄药业10%股权 成为其实控人
证券之星 · 01-01 16:50
上海医药最新公告：拟收购上海和黄药业10%股权 成为其实控人
上海医药(601607.SH)拟9.95亿元收购上海和黄药业10%股权 将成为其实控人
智通财经 · 01-01 16:47
上海医药(601607.SH)拟9.95亿元收购上海和黄药业10%股权 将成为其实控人
【上海医药：拟收购上海和黄药业10%股权】上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。
金融界 · 01-01 16:33
【上海医药：拟收购上海和黄药业10%股权】上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。
西部证券股份有限公司给予上海医药A股买进的初始评级。
金融界 · 12-31 01:13
西部证券股份有限公司给予上海医药A股买进的初始评级。
上海医药12月27日获主力加仓432万元 环比增加426.83%
市场透视 · 2024-12-27
上海医药12月27日获主力加仓432万元 环比增加426.83%
上海医药（601607）12月26日主力资金净卖出3352.03万元
证券之星 · 2024-12-27
上海医药（601607）12月26日主力资金净卖出3352.03万元
【易明医药：与上海医药合作经营的第三方产品瓜蒌皮注射液终止合作】易明医药公告，公司与上海医药集团股份有限公司子公司合作经营的产品瓜蒌皮注射液（新通®），协议于2024年12月后不再续约。该产品2024年产生的营业收入预计8500万元，占公司最近一期经审计的营业收入10%以上。合作终止是基于市场环境变化及公司战略规划调整，集中资源发展自产产品，保持自产产品业绩增长。此决策不会对公司财务及经营状况产生重大影响，不存在损害公司及中小股东权益的情形。
金融界 · 2024-12-24
【易明医药：与上海医药合作经营的第三方产品瓜蒌皮注射液终止合作】易明医药公告，公司与上海医药集团股份有限公司子公司合作经营的产品瓜蒌皮注射液（新通®），协议于2024年12月后不再续约。该产品2024年产生的营业收入预计8500万元，占公司最近一期经审计的营业收入10%以上。合作终止是基于市场环境变化及公司战略规划调整，集中资源发展自产产品，保持自产产品业绩增长。此决策不会对公司财务及经营状况产生重大影响，不存在损害公司及中小股东权益的情形。
大摩：予上海医药“增持”评级 目标价降至17港元
新浪港股 · 2024-12-24
大摩：予上海医药“增持”评级 目标价降至17港元
大摩：予上海医药(02607)“增持”评级 目标价降至17港元
智通财经 · 2024-12-24
大摩：予上海医药(02607)“增持”评级 目标价降至17港元
《大行》大摩降上海医药(02607.HK)目标价至17元 下调盈测
阿斯达克财经 · 2024-12-24
《大行》大摩降上海医药(02607.HK)目标价至17元 下调盈测
加载更多
公司概况
公司名称：
上海医药
所属市场：
SEHK
上市日期：
--
主营业务：
上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外，该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。
发行价格：
--
{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":12.62,"timestamp":1735618095032,"preClose":12.62,"halted":0,"volume":1973604,"delay":0,"floatShares":919000000,"shares":3708000000,"eps":1.0781121760771795,"marketStatus":"未开盘","change":0,"latestTime":"12-31 12:08:15","open":12.6,"high":12.7,"low":12.56,"amount":24893880,"amplitude":0.011094,"askPrice":12.62,"askSize":46800,"bidPrice":12.6,"bidSize":200500,"shortable":3,"etf":0,"ttmEps":1.1440545730664369,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735781400000},"marketStatusCode":0,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":12.62,"dividendRate":0.044475,"openAndCloseTimeList":[[1735608600000,1735617600000]],"volumeRatio":1.411295180698515,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":21,"timestamp":1735628400000,"preClose":21.04,"halted":0,"volume":11759200,"delay":0,"premium":"-43.25"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2500934655","title":"上海医药拟并表上海和黄药业 提升中药产品销售及国际化能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2500934655","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500934655?lang=zh_cn&edition=full","pubTime":"2025-01-02 01:34","pubTimestamp":1735752876,"startTime":"0","endTime":"0","summary":"1月1日晚间，上海医药集团股份有限公司（以下简称“上海医药”）发布公告称，公司拟联合上海金浦健服股权投资管理有限公司指定主体共同收购上海和黄医药投资（香港）有限公司（以下简称“和黄医药”）持有的上海和黄药业有限公司（以下简称“上海和黄药业”）股权。其中，上海医药已与和黄医药签订股份转让协议，拟以9.95亿元收购上海和黄药业10%股权（以最终国资备案价格为准）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501023284652895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","02607"],"gpt_icon":0},{"id":"2500693640","title":"上海医药拟9.95亿元收购上海和黄药业10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2500693640","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500693640?lang=zh_cn&edition=full","pubTime":"2025-01-02 00:15","pubTimestamp":1735748118,"startTime":"0","endTime":"0","summary":"1月1日晚间，上海医药（SH601607，股价21.00元，市值778.61亿元）公告称，公司拟联合上海金浦健服股权投资管理有限公司指定主体共同收购上海和黄医药投资(香港)有限公司（以下简称“和黄医药”）持有的上海和黄药业有限公司（以下简称“上海和黄药业”）股权，其中上海医药拟以9.95亿元收购10%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501023284648124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501023284648124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","02607"],"gpt_icon":0},{"id":"2500933287","title":"上海医药终止三项美国临床试验项目，累计研发投入超8000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500933287","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500933287?lang=zh_cn&edition=full","pubTime":"2025-01-01 23:36","pubTimestamp":1735745761,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0184","BK1197","BK0175","BK0097","BK0196","BK0020","03347","BK0012","BK0028","BK0099","BK0209","BK0187","BK1583","601607","BK0183","BK1141","02607","BK1576","BK0188"],"gpt_icon":0},{"id":"2500938624","title":"上海医药终止三项美国临床试验项目，累计研发投入超8000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500938624","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500938624?lang=zh_cn&edition=full","pubTime":"2025-01-01 22:40","pubTimestamp":1735742405,"startTime":"0","endTime":"0","summary":"上海医药（601607.SH）对于研发项目的调整仍在持续。2025年1月1日晚间，公司公告称，决定终止I001-B（美国）、I022（美国）、C012（美国）这三个研发项目的临床试验及后续开发。其中，I001-B（美国）及I022（美国）处于美国临床试验II期，C012（美国）获得美国食品药品监督管理局（以下简称“FDA”）I期临床试验许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501013284624548.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284624548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03347","BK1576","BK1141","02607","BK1583","BK1197"],"gpt_icon":0},{"id":"2500982273","title":"和黄医药再次剥离中药资产 上海医药拟斥资近10亿元实控和黄药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2500982273","media":"第一财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500982273?lang=zh_cn&edition=full","pubTime":"2025-01-01 21:25","pubTimestamp":1735737900,"startTime":"0","endTime":"0","summary":"交易完成后，上海医药将合计持有上海和黄药业60%股权，成为和黄药业的实际控制人。上海医药拟以自有资金人民币9.95亿元收购上海和黄药业的10%股权，交易完成后，上海医药股权比例增至60%，并对上海和黄药业实施并表。和黄医药进一步剥离中医药资产对于和黄医药来说，当下的核心业务主要聚焦在肿瘤和免疫领域的创新药研发。此次出售上海和黄药业45%的股权，是其近年来剥离中药资产的动作延续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501012129039857af03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501012129039857af03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00013","02607","BK1588","BK1587","BK1197"],"gpt_icon":0},{"id":"2500984768","title":"上海医药与云南白药2025年日常/持续关连交易金额上限为19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500984768","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500984768?lang=zh_cn&edition=full","pubTime":"2025-01-01 20:43","pubTimestamp":1735735394,"startTime":"0","endTime":"0","summary":"财中社1月1日电上海医药（601607/02607）发布关于与云南白药集团股份有限公司续签《日常关联交易/持续关连交易框架协议》的公告。根据协议，2025年1月1日至2025年12月31日，公司向云南白药销售产品金额上限为12亿元，向云南白药采购产品金额上限为7亿元。云南白药持有公司17.95%的股份，属于公司关联方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284591567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK1197"],"gpt_icon":0},{"id":"2500398583","title":"上海医药最新公告：决定终止三个研发项目的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2500398583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500398583?lang=zh_cn&edition=full","pubTime":"2025-01-01 19:00","pubTimestamp":1735729222,"startTime":"0","endTime":"0","summary":"上海医药公告，基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I001-B（美国）、I022（美国）、C012（美国）这三个研发项目的临床试验及后续开发。其中，I001-B（美国）及I022（美国）处于美国临床试验II期，C012（美国）获得FDA I期临床试验许可。公司表示，本次终止临床试验及后续开发事项，不会对公司业绩产生重大影响。公司将继续重视药品研发，并严格控制研发成本，但新药研发风险高、周期长，存在诸多不确定性。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010100007522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK1197","BK0175","BK0188","BK0099","BK0012","BK0183","BK0196","03347","BK0020","BK1583","BK0028","BK1576","BK0184","BK0187","BK1141","BK0209","601607","02607"],"gpt_icon":0},{"id":"2500988893","title":"上海医药(02607)拟以9.95亿元收购上海和黄10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2500988893","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500988893?lang=zh_cn&edition=full","pubTime":"2025-01-01 18:20","pubTimestamp":1735726825,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，于2024年12月31日，公司(买方)与和黄投资(卖方)订立股份转让协议，据此公司同意收购而和黄投资同意出售上海和黄10%股权，代价为人民币9.95亿元。同日，金浦健服与和黄投资订立股份转让协议，据此金浦健服或其指定主体将收购而和黄投资同意出售上海和黄35%股权。目标公司循证医学研究与学术推广的成功经验，将助力集团其他中药品种的开发和推广，同时进一步拓展零售及下沉市场覆盖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0183","BK1197","BK0175","BK0028","BK0196","BK0097","BK0209","BK0188","BK0187","BK0184","601607","02607","BK0099","BK0020"],"gpt_icon":0},{"id":"2500607700","title":"上海医药拟9.95亿元收购上海和黄药业10％股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2500607700","media":"大河财立方","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500607700?lang=zh_cn&edition=full","pubTime":"2025-01-01 17:30","pubTimestamp":1735723829,"startTime":"0","endTime":"0","summary":"【大河财立方消息】1月1日，上海医药公告，拟以9.95亿元自有资金收购上海和黄药业有限公司10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，对其实施并表。交易完成后，上海和黄药业三大股东上海医药、金浦健服指定主体、上海和黄医药投资(香港)有限公司的持股比例分别为60%、35%、5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284555055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","02607"],"gpt_icon":0},{"id":"2500660294","title":"上海医药(601607.SH)：拟收购上海和黄药业10%股权暨成为实际控制人","url":"https://stock-news.laohu8.com/highlight/detail?id=2500660294","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500660294?lang=zh_cn&edition=full","pubTime":"2025-01-01 17:01","pubTimestamp":1735722071,"startTime":"0","endTime":"0","summary":"格隆汇1月1日丨上海医药(601607.SH)发布公告，上海和黄药业有限公司（以下简称：“上海和黄药业”或“标的公司”）由上海医药全资子公司上海市药材有限公司（以下简称：上药药材）与上海和黄医药投资(香港)有限公司(以下简称：和黄医药)合资设立，双方各持股50%。上海医药拟联合上海金浦健服股权投资管理有限公司指定主体(以下简称：金浦健服指定主体)共同收购和黄医药持有的上海和黄药业股权。其中上海医药拟以自有资金人民币99,503.66万元(以最终国资备案价格为准)收购10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，对其实施并表。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/01170147020524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1197","601607","BK0097","BK0184","BK0187","BK0175","BK0188","BK0028","BK0196","BK0209","BK0183","BK0020","02607","BK0012","BK0099"],"gpt_icon":0},{"id":"2500160491","title":"上海医药最新公告：拟收购上海和黄药业10%股权 成为其实控人","url":"https://stock-news.laohu8.com/highlight/detail?id=2500160491","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500160491?lang=zh_cn&edition=full","pubTime":"2025-01-01 16:50","pubTimestamp":1735721414,"startTime":"0","endTime":"0","summary":"上海医药公告，上海和黄药业有限公司（简称“上海和黄药业”）由上海医药全资子公司上海市药材有限公司与上海和黄医药投资(香港)有限公司（简称“和黄医药”）合资设立，双方各持股50%。上海医药拟联合上海金浦健服股权投资管理有限公司指定主体共同收购和黄医药持有的上海和黄药业股权。其中上海医药拟以9.95亿元收购10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，对其实施并表。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010100006999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0183","BK1197","BK0175","BK0028","BK0196","BK0097","BK0209","BK0188","BK0187","BK0184","601607","02607","BK0099","BK0020"],"gpt_icon":0},{"id":"2500604643","title":"上海医药(601607.SH)拟9.95亿元收购上海和黄药业10%股权 将成为其实控人","url":"https://stock-news.laohu8.com/highlight/detail?id=2500604643","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500604643?lang=zh_cn&edition=full","pubTime":"2025-01-01 16:47","pubTimestamp":1735721232,"startTime":"0","endTime":"0","summary":"交易完成后，上海医药将合计持有上海和黄药业60%股权，对其实施并表。据悉，上海和黄药业通过大量的循证医学及学术推广工作，将麝香保心丸打造为年销售额近30亿元的心脑血管基础用药。本次交易完成后，上海和黄药业将成为公司合并报表范围内的子公司。上海和黄药业2023年度及2024年1-9月实现净利润分别为人民币6.63亿元及人民币5.73亿元，占上海医药公司同期净利润的比率分别为12.84%及11.40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0188","BK0020","BK0184","BK0196","BK0209","BK0099","BK1197","601607","BK0012","BK0175","BK0183","BK0028","BK0097","BK0187"],"gpt_icon":0},{"id":"2500601772","title":"【上海医药：拟收购上海和黄药业10%股权】上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500601772","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500601772?lang=zh_cn&edition=full","pubTime":"2025-01-01 16:33","pubTimestamp":1735720425,"startTime":"0","endTime":"0","summary":"上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/01163347020229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","BK0012","BK0175","BK1588","BK4531","159830","BK0099","BK0196","BK1587","BK0187","BK1191","00013","HCM","BK0097","BK0184","02607","BK0183","BK0020","BK4007","BK0209","BK4585","BK0188","BK4588","BK1197","601607"],"gpt_icon":0},{"id":"2495457849","title":"西部证券股份有限公司给予上海医药A股买进的初始评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2495457849","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495457849?lang=zh_cn&edition=full","pubTime":"2024-12-31 01:13","pubTimestamp":1735578806,"startTime":"0","endTime":"0","summary":"西部证券股份有限公司给予上海医药A股买进的初始评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/31011346965052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159982","002673","601607","02607","399300"],"gpt_icon":0},{"id":"2494274875","title":"上海医药12月27日获主力加仓432万元 环比增加426.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494274875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494274875?lang=zh_cn&edition=full","pubTime":"2024-12-27 16:15","pubTimestamp":1735287343,"startTime":"0","endTime":"0","summary":"12月27日, 上海医药股价跌0.31%，报收12.82元，成交金额4696万元，换手率0.40%，振幅1.40%，量比1.36。上海医药今日主力资金净流入432万元，连续5日净流入，上一交易日主力净流入82万元，今日环比增加426.83%。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为22.22%，平均涨幅为2.07%。该股近5个交易日下跌2.44%，主力资金累计净流入1074万元；近20日主力资金累计净流入5187万元，其中净流入天数为18日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227161608a20b8aff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227161608a20b8aff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02607","BK1197"],"gpt_icon":0},{"id":"2494812403","title":"上海医药（601607）12月26日主力资金净卖出3352.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2494812403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494812403?lang=zh_cn&edition=full","pubTime":"2024-12-27 08:21","pubTimestamp":1735258915,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月26日收盘，上海医药报收于20.91元，下跌3.68%，换手率1.06%，成交量20.45万手，成交额4.31亿元。12月26日的资金流向数据方面，主力资金净流出3352.03万元，占总成交额7.77%，游资资金净流入162.73万元，占总成交额0.38%，散户资金净流入3189.31万元，占总成交额7.39%。近5日资金流向一览见下表：上海医药融资融券信息显示，融资方面，当日融资买入5245.55万元，融资偿还2632.81万元，融资净买入2612.74万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122700006445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0012","BK0184","BK0196","BK0183","02607","BK0209","BK0175","BK1197","BK0187","BK0188","BK0028","BK0099","601607","BK0020"],"gpt_icon":0},{"id":"2493977143","title":"【易明医药：与上海医药合作经营的第三方产品瓜蒌皮注射液终止合作】易明医药公告，公司与上海医药集团股份有限公司子公司合作经营的产品瓜蒌皮注射液（新通®），协议于2024年12月后不再续约。该产品2024年产生的营业收入预计8500万元，占公司最近一期经审计的营业收入10%以上。合作终止是基于市场环境变化及公司战略规划调整，集中资源发展自产产品，保持自产产品业绩增长。此决策不会对公司财务及经营状况产生重大影响，不存在损害公司及中小股东权益的情形。","url":"https://stock-news.laohu8.com/highlight/detail?id=2493977143","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493977143?lang=zh_cn&edition=full","pubTime":"2024-12-24 15:49","pubTimestamp":1735026574,"startTime":"0","endTime":"0","summary":"易明医药公告，公司与上海医药集团股份有限公司子公司合作经营的产品瓜蒌皮注射液（新通®），协议于2024年12月后不再续约。该产品2024年产生的营业收入预计8500万元，占公司最近一期经审计的营业收入10%以上。合作终止是基于市场环境变化及公司战略规划调整，集中资源发展自产产品，保持自产产品业绩增长。此决策不会对公司财务及经营状况产生重大影响，不存在损害公司及中小股东权益的情形。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/24154946739359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02607","002826","601607"],"gpt_icon":0},{"id":"2493774246","title":"大摩：予上海医药“增持”评级 目标价降至17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493774246","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493774246?lang=zh_cn&edition=full","pubTime":"2024-12-24 10:05","pubTimestamp":1735005900,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 摩根士丹利发布研究报告称，上海医药（02607）公布第三财季业绩后，由于其销售疲弱，将其2024至2030年的盈测下调3%至9%，目标价由18.4港元降至17港元，评级“增持”。大摩表示，上海医药经整合的平台可提供协同与效率，而分销高价值的专利药和疫苗的需求亦有上升。另外，上海市政府对集团的支持确保其在市场的领先地位。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-12-24/doc-ineapmqw8660245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02607","601607"],"gpt_icon":0},{"id":"2493428327","title":"大摩：予上海医药(02607)“增持”评级 目标价降至17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493428327","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493428327?lang=zh_cn&edition=full","pubTime":"2024-12-24 09:54","pubTimestamp":1735005260,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研究报告称，上海医药(02607)公布第三财季业绩后，由于其销售疲弱，将其2024至2030年的盈测下调3%至9%，目标价由18.4港元降至17港元，评级“增持”。大摩表示，上海医药经整合的平台可提供协同与效率，而分销高价值的专利药和疫苗的需求亦有上升。另外，上海市政府对集团的支持确保其在市场的领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","02607"],"gpt_icon":0},{"id":"2493744639","title":"《大行》大摩降上海医药(02607.HK)目标价至17元 下调盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2493744639","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493744639?lang=zh_cn&edition=full","pubTime":"2024-12-24 09:32","pubTimestamp":1735003920,"startTime":"0","endTime":"0","summary":"摩根士丹利发表研究报告指，上海医药(02607.HK) 公布第三财业绩后，由于其销售疲弱，该行将其2024至2030年的盈测下调3至9%，目标价由18.4元降至17元，评级为“增持”。大摩表示，上海医药经整合的平台可提供协同与效率，而分销高价值的专利药和疫苗的需求亦有上升。另外，上海市政府对集团的支持亦确保其在市场的领先地位。(sl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-23 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1406125/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["601607","02607"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":-0.0292},{"period":"3month","weight":-0.0679},{"period":"6month","weight":0.0898},{"period":"1year","weight":0.1146},{"period":"ytd","weight":0.1146}],"compareEarnings":[{"period":"1week","weight":-0.0019},{"period":"1month","weight":0.0328},{"period":"3month","weight":-0.1062},{"period":"6month","weight":0.1127},{"period":"1year","weight":0.1767},{"period":"ytd","weight":0.1767}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外，该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.004804},{"month":2,"riseRate":0.615385,"avgChangeRate":0.022499},{"month":3,"riseRate":0.615385,"avgChangeRate":0.015455},{"month":4,"riseRate":0.538462,"avgChangeRate":0.003331},{"month":5,"riseRate":0.538462,"avgChangeRate":-0.00636},{"month":6,"riseRate":0.5,"avgChangeRate":-0.012586},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.020804},{"month":8,"riseRate":0.428571,"avgChangeRate":0.005824},{"month":9,"riseRate":0.357143,"avgChangeRate":0.015401},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.020412},{"month":11,"riseRate":0.428571,"avgChangeRate":0.031213},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.011642}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}